aibioProKidney files to move incorporation from the Cayman Islands to Delaware
Tickers PROK
ProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent.
Key facts
- Company
- ProKidney Corp. (NASDAQ: PROK)
- News type
- Mergers
- Primary source
- ProKidney Corp. S-4 (2025-03-31)
The domestication plan
ProKidney Corp. (Nasdaq: PROK) filed a preliminary proxy statement and prospectus on Form S-4 on March 31, 2025. The filing covers both the annual general meeting proxy and the registration of up to 292,707,888 shares of Class A and Class B common stock of the Delaware successor. The company would deregister as a Cayman Islands exempted company and continue as a Delaware corporation under Section 388 of the Delaware General Corporation Law and Sections 206 and 207 of the Cayman Islands Companies Act. The meeting date is left blank in the draft; the meeting is set for 10:00 a.m. Eastern Time at 399 Boylston Street, Boston, and by webcast.
Each Class A ordinary share would convert into one share of Class A common stock, and each Class B ordinary share into one share of Class B common stock. The Class A shares would keep trading on The Nasdaq Capital Market as PROK. The filing says there is no public market for the Class B shares. As of March 17, 2025, ProKidney had 129,536,121 Class A ordinary shares and 163,161,528 Class B ordinary shares outstanding.
Approval of the domestication requires a special resolution, meaning at least two-thirds of the Class A and Class B ordinary shares voting together. The full board and the directors who do not own Class B shares unanimously approved it. The filing says the two groups voted separately out of caution, because some directors who own Class B shares and common units in ProKidney LP are party to a Tax Receivable Agreement from the 2022 business combination. Those holders may have interests that differ from public shareholders.
The charter changes
Shareholders must also approve a new certificate of incorporation, which replaces the Cayman memorandum and articles. Both the domestication and the new charter must pass, and each vote is conditioned on the other. The filing lists five separate non-binding advisory votes on material differences between the two documents.
The advisory items include an exclusive forum for stockholder litigation in Delaware courts, and a renunciation of the company's interest in certain corporate opportunities, subject to exceptions. One would let holders of a majority of the voting power change the number of authorized shares, without a separate class vote, subject to any preferred stock. Another would replace the authorized share capital set out in the Cayman documents. The filing also says the new charter bars shareholder action by written consent, except for holders of Class B common stock and any preferred stock. Any action by shareholders must be taken at a duly called annual or special meeting.
The meeting also covers the election of three directors and ratification of Ernst & Young LLP as auditor for 2025, plus an adjournment proposal in case the domestication and charter votes fail.
Who is involved
Akin Gump Strauss Hauer & Feld LLP is ProKidney's counsel: it receives copies of communications, passes on the validity of the securities and acts as tax counsel. The filing names no financial adviser for the transaction. The board gives five reasons for the move: the predictability and flexibility of Delaware law, its governance principles, a better ability to attract and retain directors, less need for related party arrangements under transfer pricing rules, and relief from tax inefficiencies of running a U.S. operating business through a foreign corporation. ProKidney's chief executive is Bruce Culleton, M.D., and its headquarters is in Winston-Salem, North Carolina.
The business behind the vote
The filing names rilparencel as ProKidney's lead product candidate. Its risk list includes the company's reliance on third parties to conduct clinical trials for rilparencel, and its ability to manufacture the drug. The company's 2024 annual report on Form 10-K, filed March 17, 2025, describes its corporate history, which began with a July 11, 2022 business combination with Social Capital Suvretta Holdings Corp. III, a Cayman Islands special purpose company.
What comes next
The domestication cannot take effect until shareholders approve it and the other conditions are met. The draft leaves the meeting date blank and says the proxy will be mailed on or about a date not yet fixed.